FDAnews Drug Daily Bulletin

Neupro Filed With the FDA for Restless Legs Syndrome

Dec. 14, 2007
A A
The U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental new drug application (sNDA) for the use of Neupro (Rotigotine Transdermal System) as a treatment for moderate-to-severe Restless Legs Syndrome (RLS).
ABN Newswire